Drugs / CS1-CAR T Therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03710421 | Apr 2019 → Feb 2027 | plasma cell myeloma | City of Hope Medical Center | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS1-CAR T Therapy | “Procedure: CS1-CAR T Therapy” NCT03710421 ↗ |
| Action | Deplete | “These engineered immune cells, CS1-CAR T cells, may kill multiple myeloma cells.” NCT03710421 ↗ |
| Modality | Cell therapy | “These engineered immune cells, CS1-CAR T cells, may kill multiple myeloma cells.” NCT03710421 ↗ |
| Route | Intravenous | “intravenous (i.v.) delivered autologous CS1-CAR T cells” NCT03710421 ↗ |